U.K. plan to require drugmakers to pay higher rebates draws criticism from industry group

U.K. plan to require drugmakers to pay higher rebates draws criticism from industry group

A U.K. government proposal to raise mandatory rebates that drug companies are required to pay to bolster the National Health Service has sparked criticism from an industry trade group, which argues the move will undermine efforts to make life sciences a key pillar of the economy. At issue is a program called the statutory scheme, which was created several years ago and is one of two initiatives in which the government uses rebates to cap the cos…